J&J to provide U.S. with 100M doses of COVID-19 vaccine

By The Science Advisory Board staff writers

August 5, 2020 -- Johnson & Johnson will manufacture and deliver 100 million doses of its SARS-CoV-2 investigational vaccine to the U.S. government once it receives regulatory approval from the U.S. Food and Drug Administration (FDA).

Funding of over $1 billion will be provided by the U.S. Biomedical Advanced Research and Development Authority (BARDA) in collaboration with the U.S. Department of Defense. Under the agreement, the vaccine, Ad26.COV2.S, will be provided at a global not-for-profit basis for emergency pandemic use. The U.S. government may also purchase an additional 200 million doses under an additional agreement.

The company is conducting research and development in collaboration with BARDA and oversight from the FDA. Recently published phase I/IIa clinical trial results were positive and the company is currently evaluating both one- and two-dose regimens.

J&J reports positive preclinical results for COVID-19 vaccine
Johnson & Johnson reported that its lead COVID-19 vaccine candidate protected against SARS-CoV-2 in preclinical studies.
J&J to start clinical trial for COVID-19 vaccine in July
Johnson & Johnson is accelerating its investigational SARS-CoV-2 vaccine candidate, Ad26.COV2-S, recombinant, with the initiation of a phase I/IIA...
J&J announces manufacturing collaboration for COVID-19 vaccine
Johnson & Johnson, a Janssen Pharmaceuticals company, announced on April 24 a collaboration with Emergent BioSolutions to support the manufacturing...
J&J seeks to release COVID-19 vaccine by 2021
Johnson & Johnson has selected a lead COVID-19 vaccine candidate from a number of options it has been working on since January. The company hopes...

Copyright © 2020 scienceboard.net


Conferences
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter